TransMedics Group, Inc. (TMDX)

TMDX Income Statement

Revenue, expenses, and profitability analysis

TMDX Quarterly Income Statement (USD)

Quarterly Report	TTM	03/31/2026	12/31/2025	09/30/2025	06/30/2025	03/31/2025	12/31/2024	09/30/2024	06/30/2024
Revenue	635.890M	173.933M	160.764M	143.823M	157.370M	143.537M	121.624M	108.761M	114.305M
Cost of Goods Sold	260.151M	72.772M	67.350M	59.248M	60.781M	55.309M	49.611M	47.916M	45.144M
Gross Profit	375.739M	101.161M	93.414M	84.575M	96.589M	88.228M	72.013M	60.845M	69.161M
Gross Profit Margin	58.2%	58.2%	58.1%	58.8%	61.4%	61.5%	59.2%	55.9%	60.5%
Total Operating Expenses	281.302M	87.864M	72.141M	61.275M	60.022M	60.785M	63.369M	56.922M	56.653M
Research & Development	76.774M	24.879M	20.701M	15.260M	15.934M	17.160M	16.464M	14.266M	13.858M
Selling, General & Administrative	198.466M	56.923M	51.440M	46.015M	44.088M	43.625M	46.905M	42.656M	42.795M
Operating Income (EBIT)	94.437M	13.297M	21.273M	23.300M	36.567M	27.443M	8.644M	3.923M	12.508M
Operating Margin	7.6%	7.6%	13.2%	16.2%	23.2%	19.1%	7.1%	3.6%	10.9%
Income Before Tax (EBT)	89.331M	8.485M	21.633M	23.031M	36.182M	26.676M	6.989M	4.245M	12.153M
Interest Income	5.458M	2.958M	—	—	2.500M	—	2.916M	3.300M	3.400M
Interest Expense	17.491M	7.170M	3.354M	3.491M	3.476M	3.461M	3.571M	3.617M	3.623M
Other Income/Expense	-5.106M	-4.812M	360K	-269K	-385K	-767K	-1.655M	322K	-355K
Net Income	171.924M	7.315M	105.383M	24.319M	34.907M	25.682M	6.857M	4.216M	12.194M
Income Tax Expense	-82.593M	1.170M	-83.750M	-1.288M	1.275M	994K	132K	29K	-41K
Net Profit Margin	4.2%	4.2%	65.6%	16.9%	22.2%	17.9%	5.6%	3.9%	10.7%
EBITDA	139.734M	27.519M	32.455M	33.371M	46.389M	36.274M	16.240M	13.039M	20.375M
EBITDA Margin	15.8%	15.8%	20.2%	23.2%	29.5%	25.3%	13.4%	12.0%	17.8%
Depreciation & Amortization	32.912M	11.864M	7.468M	6.849M	6.731M	6.137M	5.680M	5.177M	4.599M
EPS Basic	5.03	0.21	3.08	0.71	1.03	0.76	0.20	0.13	0.37
EPS Diluted	4.37	0.20	2.59	0.66	0.92	0.70	0.19	0.12	0.35
Shares Outstanding	34.384M	34.384M	34.220M	34.112M	33.913M	33.722M	33.592M	33.441M	33.120M
Diluted Shares Outstanding	36.194M	36.194M	40.928M	40.748M	40.559M	39.914M	35.211M	35.684M	35.288M

TMDX Annual Income Statement (USD)

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	605.494M	441.540M	241.623M	93.459M	30.262M	25.639M	23.604M	13.017M
Cost of Goods Sold	242.688M	179.459M	87.530M	28.187M	9.103M	9.004M	9.741M	7.283M
Gross Profit	362.806M	262.081M	154.093M	65.272M	21.159M	16.635M	13.863M	5.734M
Gross Profit Margin	59.9%	59.4%	63.8%	69.8%	69.9%	64.9%	58.7%	44.1%
Total Operating Expenses	254.223M	224.585M	182.820M	96.709M	60.587M	43.019M	43.466M	25.971M
Research & Development	69.055M	55.968M	63.267M	26.812M	22.304M	18.831M	19.870M	13.656M
Selling, General & Administrative	185.168M	168.617M	119.553M	69.897M	38.283M	24.188M	23.596M	12.315M
Operating Income (EBIT)	108.583M	37.496M	-28.727M	-31.437M	-39.428M	-26.384M	-29.603M	-20.237M
Operating Margin	17.9%	8.5%	-11.9%	-33.6%	-130.3%	-102.9%	-125.4%	-155.5%
Income Before Tax (EBT)	107.522M	35.780M	-26.671M	-36.165M	-44.179M	-28.716M	-33.507M	-23.715M
Interest Income	—	—	12.500M	900K	—	1.653M	790K	—
Interest Expense	13.782M	14.409M	10.791M	3.726M	3.874M	3.985M	4.353M	2.420M
Other Income/Expense	-1.061M	-1.716M	2.056M	-4.728M	-4.751M	-2.332M	-3.904M	-3.478M
Net Income	190.291M	35.464M	-25.028M	-36.231M	-44.215M	-28.748M	-33.547M	-23.756M
Income Tax Expense	-82.769M	316K	-1.643M	66K	36K	32K	40K	41K
Net Profit Margin	31.4%	8.0%	-10.4%	-38.8%	-146.1%	-112.1%	-142.1%	-182.5%
EBITDA	148.489M	69.947M	-7.703M	-28.961M	-38.488M	-23.154M	-27.932M	-20.226M
EBITDA Margin	24.5%	15.8%	-3.2%	-31.0%	-127.2%	-90.3%	-118.3%	-155.4%
Depreciation & Amortization	27.185M	19.758M	8.177M	3.478M	1.817M	1.577M	1.222M	769K
EPS Basic	5.60	1.07	-0.77	-1.23	-1.60	-1.16	-2.36	-1.23
EPS Diluted	4.87	1.01	-0.77	-1.23	-1.60	-1.16	-2.36	-1.23
Shares Outstanding	33.993M	33.230M	32.517M	29.557M	27.617M	24.703M	14.205M	19.246M
Diluted Shares Outstanding	40.541M	35.217M	32.517M	29.557M	27.617M	24.703M	14.205M	19.246M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.

About TransMedics Group, Inc.

TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.

Andover, MA

728 employees

www.transmedics.com

Healthcare / Medical - Devices

Sector: Healthcare
Industry: Medical - Devices
CEO: Waleed H. Hassanein

View full financials